use of adult stem cells and induced pluripotent stem (iPS) cells. However, it hasn’t all been smooth sailing. Although after protracted forethought, the US Food and Drug Administration (FDA) gave the green light for the Californian biotech Geron to begin the very first human clinical trial of a human embryonic stem cell-derived ther

em and come up with a drug to fix it. But because the United States Food and Drug Administration already has a library of approved compounds that

analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute Valencia. It has not been cleared or approved by the US Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. (3) Performed by: Quest Diagnostics Nichols In

risks to the company's shares include reimbursement pressure once Medicare and private payors start covering Foundation's tests, Murphy said. Also, the US Food and Drug Administration may take steps to increase regulation of laboratory-developed tests such as FoundationOne and FoundationOne Heme. The company could also face incre